MCID: CNT037
MIFTS: 31

Central Nervous System Germinoma malady

Categories: Rare diseases, Neuronal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Central Nervous System Germinoma

Aliases & Descriptions for Central Nervous System Germinoma:

Name: Central Nervous System Germinoma 12 50 14 69
Intracranial Germinoma 50 56 69
Germinoma of the Central Nervous System 50 56
Germinoma of Cns 12

Characteristics:

Orphanet epidemiological data:

56
germinoma of the central nervous system
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:



External Ids:

Disease Ontology 12 DOID:4438
NCIt 47 C7009
Orphanet 56 ORPHA91352
UMLS 69 C1333813

Summaries for Central Nervous System Germinoma

MalaCards based summary : Central Nervous System Germinoma, also known as intracranial germinoma, is related to childhood central nervous system germinoma and adult central nervous system germinoma. An important gene associated with Central Nervous System Germinoma is JMJD1C (Jumonji Domain Containing 1C), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and G alpha (s) signalling events. The drugs Etoposide and Cisplatin have been mentioned in the context of this disorder.

Related Diseases for Central Nervous System Germinoma

Diseases in the Central Nervous System Germinoma family:

Adult Central Nervous System Germinoma

Diseases related to Central Nervous System Germinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 childhood central nervous system germinoma 12.2
2 adult central nervous system germinoma 12.2
3 brain germinoma 11.1
4 paranasal sinus cancer 10.1 POMC POU5F1
5 bagassosis 10.0 AVP POMC
6 central nervous system sarcoma 10.0 AVP POU5F1
7 glossopharyngeal nerve neoplasm 10.0 AVP POMC
8 gonococcal seminal vesiculitis 10.0 AVP POMC
9 mediastinitis 10.0
10 kindler syndrome 10.0 AVP POMC
11 autosomal recessive nonsyndromic deafness 10.0 ALPP POMC
12 bone benign neoplasm 10.0 AVP POMC
13 syringomelia hyperkeratosis 9.9 AVP POMC
14 pharynx cancer 9.9 AVP POMC
15 astroblastoma 9.9 AVP POMC
16 sternum lymphoma 9.9 AVP POMC
17 diencephalic neoplasm 9.9 AVP POMC
18 encephalopathy, neonatal severe 9.9 JMJD1C POMC
19 mucopolysaccharidosis type vi 9.9 AVP POMC
20 seminoma 9.9
21 diabetes insipidus 9.9
22 urethra clear cell adenocarcinoma 9.9 AVP POMC
23 fatty liver disease 9.9 AVP POMC
24 chondroma 9.9 AVP POMC
25 embryonal carcinoma 9.8
26 peritonitis 9.8
27 medulloblastoma 9.8
28 meningitis 9.8
29 calcinosis 9.8 AVP POMC
30 childhood kidney cell carcinoma 9.8 AVP POMC POU5F1
31 mitochondrial dna depletion syndrome 5 9.7 AVP POMC
32 smith-lemli-opitz syndrome 9.7
33 cauda equina syndrome 9.7
34 cornelia de lange syndrome 9.7
35 klinefelter's syndrome 9.7
36 teratoma 9.7
37 choriocarcinoma 9.7
38 polyradiculopathy 9.7
39 neuronitis 9.7
40 lymphocytic hypophysitis 9.7
41 testicular seminoma 9.7
42 tremor 9.7
43 growing teratoma syndrome 9.7
44 macular retinal edema 9.3 ALPP AVP JMJD1C POMC POU5F1

Graphical network of the top 20 diseases related to Central Nervous System Germinoma:



Diseases related to Central Nervous System Germinoma

Symptoms & Phenotypes for Central Nervous System Germinoma

Drugs & Therapeutics for Central Nervous System Germinoma

Drugs for Central Nervous System Germinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
6
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
8
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
9 Alkylating Agents Phase 3,Phase 2,Phase 1
10 Adjuvants, Immunologic Phase 3,Phase 1
11 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
12 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
13 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
14 Etoposide phosphate Phase 3,Phase 2,Phase 1
15 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
16 Antiemetics Phase 3,Phase 2,Phase 1
17 Antirheumatic Agents Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
19 Autonomic Agents Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Dexamethasone acetate Phase 3,Phase 1 1177-87-3
22 Dexamethasone 21-phosphate Phase 3,Phase 1
23 Emetics Phase 3
24 BB 1101 Phase 3,Phase 1
25
Ifosfamide Approved Phase 2,Phase 1 3778-73-2 3690
26
Mechlorethamine Approved Phase 2,Phase 1 51-75-2 4033
27
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
28
Thiotepa Approved Phase 2,Phase 1 52-24-4 5453
29
Bleomycin Approved Phase 2 11056-06-7 5360373
30
Palbociclib Approved Phase 2 571190-30-2 11431660 5005498 5330286
31
nivolumab Approved Phase 2 946414-94-4
32
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
33
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
34
Serotonin Phase 2 50-67-9 5202
35 Serotonin Agents Phase 2
36 Serotonin Antagonists Phase 2
37 Neurotransmitter Agents Phase 2
38 Dermatologic Agents Phase 2,Phase 1
39 Tranquilizing Agents Phase 2
40 Anti-Anxiety Agents Phase 2
41 Protein Kinase Inhibitors Phase 2,Phase 1
42 Psychotropic Drugs Phase 2
43 Isophosphamide mustard Phase 2,Phase 1
44 Antipsychotic Agents Phase 2
45 Central Nervous System Depressants Phase 2
46 Antipruritics Phase 2
47 Ether Phase 2,Phase 1
48 Cyclin-Dependent Kinase Inhibitor Proteins Phase 2
49 Hematoporphyrin Derivative Phase 2,Phase 1
50 Hematoporphyrins Phase 2,Phase 1

Interventional clinical trials:

(show all 32)
id Name Status NCT ID Phase
1 Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor Completed NCT00085098 Phase 3
2 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
3 Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors Completed NCT00002472 Phase 2
4 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed NCT00047320 Phase 2
5 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2
6 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2
7 Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma Recruiting NCT02782754 Phase 2
8 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting NCT01037790 Phase 2
9 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Recruiting NCT01966809 Phase 2
10 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
11 Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Active, not recruiting NCT01602666 Phase 2
12 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2
13 Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors Terminated NCT01808534 Phase 2
14 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1
15 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1
16 Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Completed NCT00281944 Phase 1
17 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1
18 Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Completed NCT00929903 Phase 1
19 Sunitinib in Treating Young Patients With Refractory Solid Tumors Completed NCT00387920 Phase 1
20 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1
21 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1
22 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1
23 Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER- Completed NCT00228358 Phase 1
24 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
25 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Recruiting NCT01682746 Phase 1
26 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1
27 Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1
28 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant Completed NCT00408681
29 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
30 Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors Recruiting NCT01445288
31 Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Active, not recruiting NCT00638898
32 Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors Withdrawn NCT00897858

Search NIH Clinical Center for Central Nervous System Germinoma

Genetic Tests for Central Nervous System Germinoma

Anatomical Context for Central Nervous System Germinoma

Publications for Central Nervous System Germinoma

Articles related to Central Nervous System Germinoma:

(show all 16)
id Title Authors Year
1
Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. ( 26744133 )
2016
2
Improvement of Long-term Results with Neoadjuvant Chemotherapy andA Radiotherapy for Central Nervous System Germinoma. ( 26115804 )
2015
3
Feasibility of dasatinib in children and adolescents with new or recurrent central nervous system germinoma. ( 23754592 )
2013
4
An unusual case of primary central nervous system germinoma with meningeal dissemination. ( 22936081 )
2012
5
Neurocognitive outcomes in pediatric and adolescent patients with central nervous system germinoma treated with a strategy of chemotherapy followed by reduced-dose and volume irradiation. ( 21495164 )
2011
6
Outcome of central nervous system germinoma treatment by chemoradiation. ( 21516012 )
2011
7
Regression of primary central nervous system germinoma after dexamethasone administration: a case report. ( 20367268 )
2010
8
Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma. ( 20045266 )
2010
9
Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. ( 19326417 )
2009
10
Management of central nervous system germinoma: proposal for a modern strategy. ( 19329866 )
2009
11
Diffusion-weighted imaging characteristics of primary central nervous system germinoma with histopathologic correlation: a retrospective study. ( 19643635 )
2009
12
OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma. ( 15725806 )
2005
13
Patterns of failure after induction chemotherapy followed by consolidative radiation therapy for children with central nervous system germinoma. ( 14595717 )
2003
14
Induction chemotherapy followed by reduced-volume radiation therapy for newly diagnosed central nervous system germinoma. ( 9420074 )
1998
15
Radiation therapy for histologically confirmed primary central nervous system germinoma. ( 9276355 )
1997
16
Hormonal and metabolic abnormalities associated with central nervous system germinoma in children and adolescents and the effect of therapy: report of 10 patients. ( 6256407 )
1981

Variations for Central Nervous System Germinoma

Expression for Central Nervous System Germinoma

Search GEO for disease gene expression data for Central Nervous System Germinoma.

Pathways for Central Nervous System Germinoma

Pathways related to Central Nervous System Germinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.37 AVP POU5F1
2 11.12 AVP POMC
3 10.75 ALPP POU5F1

GO Terms for Central Nervous System Germinoma

Cellular components related to Central Nervous System Germinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.62 AVP POMC

Biological processes related to Central Nervous System Germinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 generation of precursor metabolites and energy GO:0006091 8.62 AVP POMC

Molecular functions related to Central Nervous System Germinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.96 AVP POMC
2 transcription regulatory region sequence-specific DNA binding GO:0000976 8.62 JMJD1C POU5F1

Sources for Central Nervous System Germinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....